Loading stock data…
LENZ Therapeutics (LENZ)
$5.76-0.06 (-1.03%)
After Hours$5.87+0.11 (+1.91%)· Last close Jun 29
LENZ Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
LENZ Therapeutics, Inc. in the Healthcare sector is trading at $5.76 with a market capitalization of $203M. Wall Street consensus targets $32.00 (7 analysts), implying a +455.6% move over the next 12 months. The stock is currently near its 52-week low of $5.23, remaining 69.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the safe zone. Risk note: RSI 29 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +455.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 29) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.90M↑ | $1.59M↓ | $12.50M↑ | $5.00M | $0 |
| Gross Profit | $825,000 | — | — | — | $0 |
| Operating Income | -$44.13M↓ | -$38.46M↓ | -$18.89M↓ | -$16.86M↑ | -$16.93M |
| Net Income | -$41.49M↓ | -$35.90M↓ | -$16.70M↓ | -$14.91M↓ | -$14.62M |
Peer Comparison
JNJUNHPFE
Fundamentals
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of pre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$203.49M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-44.22%
Volume
Today's trading volume
594,124
Recent News
LENZ Therapeutics adds China partner for presbyopia drug VIZZ
LENZ Therapeutics, Inc. (NASDAQ:LENZ) said Everest Medicines has acquired the rights to develop and commercialize VIZZ, also known as LNZ100, in Greater China. Under the agreement, Everest Medicines (HKEX:1952) takes on development and commercialization of the drug in the Greater China...
Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade
The analysts covering LENZ Therapeutics, Inc. ( NASDAQ:LENZ ) delivered a dose of negativity to shareholders today, by...
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates
It's been a sad week for LENZ Therapeutics, Inc. ( NASDAQ:LENZ ), who've watched their investment drop 17% to US$8.05...
Top Midday Decliners
Power Solutions International (PSIX) reported late Monday lower-than-expected adjusted EPS and reven
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls
Toast downgraded, Lowe's upgraded: Wall Street's top analyst calls